Please assess the completion status of the following clinical trial:

Trial Title: An Exploratory Study of Naltrexone Plus Aripiprazole for Alcohol Dependence

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: FACTORIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. Age 18 70~2. Subjects will meet criteria for primary alcohol dependence operationalized as follows:~   A. Meets the DSM IV criteria for alcohol dependence including loss of control over drinking (criterion 3) B. Has not had more than one previous inpatient medical detoxification~3. Consumes, on average, at least 10 standard drinks per drinking day for men and 8 drinks per day for women in the 90 days pre-screening (to select an appropriately heavy drinking population)~4. Able to maintain sobriety for four days (with or without the aid of alcohol detoxification medications) as determined by self report, collateral report, and breathalyzer measurements~5. Able to read and understand questionnaires and informed consent~6. Lives within approximately 50 miles of the study site -~Exclusion Criteria:~1. Currently meets DSM IV criteria for any other psychoactive substance dependency disorder except nicotine dependence~2. Ever abused opiates~3. Any psychoactive substance abuse, except marijuana and nicotine, within the last 30 days as evidenced by subject report, collateral report, or urine drug screen~4. Meets DSM IV criteria for current axis I disorders of major depression, panic disorder, obsessive compulsive disorder, post traumatic stress syndrome, bipolar affective disorder, schizophrenia, or any other psychotic disorder or organic mental disorder~5. Meets DSM IV current criteria for dissociative disorder or eating disorders~6. Has current suicidal ideation or homicidal ideation~7. Need for maintenance or acute treatment with any psychoactive medication including anti-seizure medications~8. Current use of disulfiram~9. Clinically significant medical problems such as cardiovascular, renal, GI, or endocrine problem that would impair participation or limit medication ingestion~10. Hepatocellular disease indicated by elevations of SGPT (ALT) and SGOT (AST) of at least 3.0 times normal at screening and/or after 5 days abstinence~11. Sexually active female of child-bearing potential who is pregnant (by urine HCG), nursing, or who is not using a reliable form of birth control~12. Has current charges pending for a violent crime (not including DUI-related offenses)~13. Does not have a stable living situation and a reliable source of collateral reporting~14. Has taken an opiate antagonist drug in the last month~15. Has taken aripiprazole in the last month or has experienced adverse effects from it at any time in the past

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: PLACEBO_COMPARATOR): None
- 2 (Type: ACTIVE_COMPARATOR): Naltrexone
- 3 (Type: ACTIVE_COMPARATOR): Naltrexone + Aripiprazole

Based on this trial design, predict the completion outcome and termination type (if applicable).